338 related articles for article (PubMed ID: 11421302)
21. Autologous hematopoietic stem cell transplantation for autoimmune diseases.
Gratwohl A; Passweg J; Bocelli-Tyndall C; Fassas A; van Laar JM; Farge D; Andolina M; Arnold R; Carreras E; Finke J; Kötter I; Kozak T; Lisukov I; Löwenberg B; Marmont A; Moore J; Saccardi R; Snowden JA; van den Hoogen F; Wulffraat NM; Zhao XW; Tyndall A;
Bone Marrow Transplant; 2005 May; 35(9):869-79. PubMed ID: 15765114
[TBL] [Abstract][Full Text] [Related]
22. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A;
Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
24. [A preliminary study on the treatment of severe autoimmune disease by autologous peripheral CD(34)(+) cell transplantation].
Zhou DB; Zhao Y; Wang SJ; Li TS; Zhang JP; Zhao YQ; Duan Y; Zhang FC; Tang FL; Bai LJ; Cui W; Wu P; Zhang FQ; Shen T
Zhonghua Xue Ye Xue Za Zhi; 2003 Sep; 24(9):460-3. PubMed ID: 14575587
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
26. [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases].
Chen H; Lu DP; Huang XJ; Liu KY; Xu LP; Han W; Ren HY; Chen YH; Liu DH; Lu J; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):273-6. PubMed ID: 15949287
[TBL] [Abstract][Full Text] [Related]
27. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis.
Vonk MC; Marjanovic Z; van den Hoogen FH; Zohar S; Schattenberg AV; Fibbe WE; Larghero J; Gluckman E; Preijers FW; van Dijk AP; Bax JJ; Roblot P; van Riel PL; van Laar JM; Farge D
Ann Rheum Dis; 2008 Jan; 67(1):98-104. PubMed ID: 17526554
[TBL] [Abstract][Full Text] [Related]
29. Autologous hematopoietic stem cell transplantation for severe autoimmune disease with special reference to rheumatoid arthritis.
Tyndall A;
J Rheumatol Suppl; 2001 Oct; 64():5-7. PubMed ID: 11642506
[TBL] [Abstract][Full Text] [Related]
30. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
31. [Transplantation of purified CD34+ stem cells from autologous peripheral blood for treatment of systemic lupus erythematosus].
Zeng K; Peng XB; Sun J; Xu D; Meng FY
Di Yi Jun Yi Da Xue Xue Bao; 2002 Nov; 22(11):1052. PubMed ID: 12433652
[TBL] [Abstract][Full Text] [Related]
32. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus.
Lisukov IA; Sizikova SA; Kulagin AD; Kruchkova IV; Gilevich AV; Konenkova LP; Zonova EV; Chernykh ER; Leplina OY; Sentyakova TN; Demin AA; Kozlov VA
Lupus; 2004; 13(2):89-94. PubMed ID: 14995000
[TBL] [Abstract][Full Text] [Related]
33. Collection of hematopoietic stem cells from patients with autoimmune diseases.
Burt RK; Fassas A; Snowden J; van Laar JM; Kozak T; Wulffraat NM; Nash RA; Dunbar CE; Arnold R; Prentice G; Bingham S; Marmont AM; McSweeney PA
Bone Marrow Transplant; 2001 Jul; 28(1):1-12. PubMed ID: 11498738
[TBL] [Abstract][Full Text] [Related]
34. Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Castagna L; Bertuzzi A; Nozza A; Siracusano L; Balzarotti M; Magagnoli M; Sarina B; Timofeeva I; Sinnone M; Grimoldi MG; Farè M; Santoro A
Bone Marrow Transplant; 2002 Aug; 30(4):207-14. PubMed ID: 12203136
[TBL] [Abstract][Full Text] [Related]
35. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
36. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease.
Tsukamoto H; Nagafuji K; Horiuchi T; Miyamoto T; Aoki K; Takase K; Henzan H; Himeji D; Koyama T; Miyake K; Inoue Y; Nakashima H; Otsuka T; Tanaka Y; Nagasawa K; Harada M
Ann Rheum Dis; 2006 Apr; 65(4):508-14. PubMed ID: 16126798
[TBL] [Abstract][Full Text] [Related]
37. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis.
Oyama Y; Barr WG; Statkute L; Corbridge T; Gonda EA; Jovanovic B; Testori A; Burt RK
Bone Marrow Transplant; 2007 Sep; 40(6):549-55. PubMed ID: 17646844
[TBL] [Abstract][Full Text] [Related]
38. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
[TBL] [Abstract][Full Text] [Related]
39. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
[TBL] [Abstract][Full Text] [Related]
40. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients.
Carreras E; Saiz A; Marín P; Martínez C; Rovira M; Villamor N; Aymerich M; Lozano M; Fernández-Avilés F; Urbano-Izpizua A; Montserrat E; Graus F
Haematologica; 2003 Mar; 88(3):306-14. PubMed ID: 12651270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
